CN104398571A - Red sage root heart-soothing capsule and preparation method thereof - Google Patents
Red sage root heart-soothing capsule and preparation method thereof Download PDFInfo
- Publication number
- CN104398571A CN104398571A CN201410618752.4A CN201410618752A CN104398571A CN 104398571 A CN104398571 A CN 104398571A CN 201410618752 A CN201410618752 A CN 201410618752A CN 104398571 A CN104398571 A CN 104398571A
- Authority
- CN
- China
- Prior art keywords
- heart
- carbon dioxide
- ground
- extracting solution
- soothing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 240000007164 Salvia officinalis Species 0.000 title abstract 5
- 235000005412 red sage Nutrition 0.000 title abstract 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 15
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 15
- 238000000227 grinding Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 8
- 241001072909 Salvia Species 0.000 claims description 29
- 235000017276 Salvia Nutrition 0.000 claims description 29
- 239000006071 cream Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 108010011485 Aspartame Proteins 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 8
- 229960003438 aspartame Drugs 0.000 claims description 8
- 235000010357 aspartame Nutrition 0.000 claims description 8
- 239000000605 aspartame Substances 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 8
- 238000004132 cross linking Methods 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 206010013786 Dry skin Diseases 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000005550 wet granulation Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 3
- 241000233839 Commelina communis Species 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a red sage root heart-soothing capsule and a preparation method thereof. The preparation method is characterized by comprising the following steps: preparing 1000 grams of red sage root and 250 grams of commelina communis, extracting the raw materials by a carbon dioxide supercritical extraction method, then drying the extract under reduced pressure, grinding the extract by high energy nano impact to obtain nano dry paste, and adding functional auxiliary materials so as to obtain the red sage root heart-soothing capsule. The disintegration time of the capsule is prominently shortened, the curative effect of the provided capsule prominently better than those of red sage heart-soothing capsules in the market, and a positive effect is achieved.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of salvia heart-soothing capsules and preparation method thereof.
Background technology
Salvia heart-soothing capsules blood circulation promoting and blood stasis dispelling, tranquillizing and allaying excitement.For the angina pectoris that coronary heart disease causes, uncomfortable in chest and cardiopalmus etc.Commercially available salvia heart-soothing capsules is due to prescription and technological reason, and curative effect is not satisfactory, and preparation adopts traditional handicraft preparation, there is the deficiencies such as stripping is slow, curative effect is low.
Summary of the invention
The present invention, for overcoming above-mentioned deficiency, provides salvia heart-soothing capsules that a kind of dissolution rate is fast, curative effect is high and preparation method thereof.
Invention embodiment is as follows:
Get Radix Salviae Miltiorrhizae 1000g, Herba Commelinae 250g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 30 ~ 40Mpa, extraction temperature 30 ~ 40 DEG C, separator pressure 10 ~ 20Mpa, separator temperature 50 ~ 60 DEG C, disengaging time 2 ~ 4 hours, carbon dioxide flow 40 ~ 50L per hour, obtains extracting solution; Get extracting solution 60 DEG C ~ 80 DEG C drying under reduced pressure, get dry extract; Get dry cream and add aspartame 150 ~ 200g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200 ~ 300nm; Get mixing dried cream powder, microcrystalline Cellulose 45 ~ 55g, crospolyvinylpyrrolidone 45 ~ 55g, cross-linking sodium carboxymethyl cellulose 35 ~ 45g, mix homogeneously, with 50 ~ 70% ethanol wet granulations, 60 DEG C ~ 80 DEG C dryings, additional carboxymethyl starch sodium 7 ~ 9g, magnesium stearate 1 ~ 3g, granulate, incapsulates, obtained salvia heart-soothing capsules 1000.
The raw material standards that above-mentioned embodiment is mentioned is as follows:
Radix Salviae Miltiorrhizae: China's coastal port one ministerial standard.This product is the dry root and rhizome of labiate Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bge..Spring, Qiu Erji excavate, removing silt, dry.
Herba Commelinae: China's coastal port one ministerial standard.This product is the dry aerial parts of Commelianaceae plant duck grass Commelina communis L..Summer, Qiu Erji gather, and dry.
Aspartame: Chinese Pharmacopoeia version two ministerial standard in 2010.
Microcrystalline Cellulose: Chinese Pharmacopoeia version two ministerial standard in 2010.
Crospolyvinylpyrrolidone: Chinese Pharmacopoeia version two ministerial standard in 2010.
Cross-linking sodium carboxymethyl cellulose: Chinese Pharmacopoeia version two ministerial standard in 2010.
Carboxymethyl starch sodium: Chinese Pharmacopoeia version two ministerial standard in 2010.
Magnesium stearate: Chinese Pharmacopoeia version two ministerial standard in 2010.
Raw material used by above salvia heart-soothing capsules all can be bought from pharmaceuticals and obtain, and all can be used to implement the present invention program as long as meet national standard.
In foregoing invention scheme, term used is pharmacy proprietary term, as " decompression " etc. all defers to Chinese Pharmacopoeia regulation and pharmaceutical practice of being correlated with.
Unit g in the present invention also can be other weight portion, does not affect the enforcement of the present invention program.
Equipment Market described in the present invention program all has sale, is not limited to typical production producer, as long as technical specification can reach requirement, all can be used to realize the present invention.
Detailed description of the invention
Specific embodiments of the invention 1
Get Radix Salviae Miltiorrhizae 1000g, Herba Commelinae 250g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 30Mpa, extraction temperature 30 DEG C, separator pressure 10Mpa, separator temperature 50 DEG C, disengaging time 2 hours, carbon dioxide flow 40L per hour, obtains extracting solution; Get extracting solution 60 DEG C of drying under reduced pressure, get dry extract; Get dry cream and add aspartame 150g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200 ~ 300nm; Get mixing dried cream powder, microcrystalline Cellulose 45g, crospolyvinylpyrrolidone 45g, cross-linking sodium carboxymethyl cellulose 35g, mix homogeneously, with 50% ethanol wet granulation, 60 DEG C of dryings, additional carboxymethyl starch sodium 7g, magnesium stearate 1g, granulate, incapsulates, obtained salvia heart-soothing capsules 1000.
Specific embodiments of the invention 2
Get Radix Salviae Miltiorrhizae 1000g, Herba Commelinae 250g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 40Mpa, extraction temperature 40 DEG C, separator pressure 20Mpa, separator temperature 60 DEG C, disengaging time 4 hours, carbon dioxide flow 50L per hour, obtains extracting solution; Get extracting solution 80 DEG C of drying under reduced pressure, get dry extract; Get dry cream and add aspartame 200g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200 ~ 300nm; Get mixing dried cream powder, microcrystalline Cellulose 55g, crospolyvinylpyrrolidone 55g, cross-linking sodium carboxymethyl cellulose 45g, mix homogeneously, with 70% ethanol wet granulation, 80 DEG C of dryings, additional carboxymethyl starch sodium 9g, magnesium stearate 3g, granulate, incapsulates, obtained salvia heart-soothing capsules 1000.
Specific embodiments of the invention 3
Get Radix Salviae Miltiorrhizae 1000g, Herba Commelinae 250g, be ground into 60 order coarse powder, adopt carbon dioxide supercritical extraction method to extract, extracting pressure 35Mpa, extraction temperature 35 DEG C, separator pressure 15Mpa, separator temperature 55 DEG C, disengaging time 3 hours, carbon dioxide flow 45L per hour, obtains extracting solution; Get extracting solution 70 DEG C of drying under reduced pressure, get dry extract; Get dry cream and add aspartame 175g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200 ~ 300nm; Get mixing dried cream powder, microcrystalline Cellulose 50g, crospolyvinylpyrrolidone 50g, cross-linking sodium carboxymethyl cellulose 40g, mix homogeneously, with 60% ethanol wet granulation, 70 DEG C of dryings, additional carboxymethyl starch sodium 8g, magnesium stearate 2g, granulate, incapsulates, obtained salvia heart-soothing capsules 1000.
Above embodiment illustrates, adopts the extreme condition of embodiment of the present invention and optimal conditions all can make salvia heart-soothing capsules.Actual effect of the present invention is investigated below with the salvia heart-soothing capsules that embodiment 3 is obtained:
(1) embodiment 3 salvia heart-soothing capsules and the contrast of commercially available salvia heart-soothing capsules dissolution limit
1 dissolution limit assay method
Measure by Chinese Pharmacopoeia version annex Ⅻ A in 2010.
2 dissolution limit contrasts
Table 1 embodiment 3 salvia heart-soothing capsules and commercially available salvia heart-soothing capsules dissolution limit contrast table
The above results shows, salvia heart-soothing capsules prepared by the present invention has the remarkable advantages such as dissolution rate is fast, bioavailability is high relative to commercially available salvia heart-soothing capsules.
(2) embodiment 3 salvia heart-soothing capsules and commercially available salvia heart-soothing capsules treatment angina pectoris Disease Clinical observation of curative effect
1 case scenario
Statistics outpatient service and inpatient, observe angina pectoris disease case 150 example, 49 years old mean age altogether.Patient is divided into two groups, test group takes embodiment 3 salvia heart-soothing capsules, and matched group takes commercially available salvia heart-soothing capsules.
2 efficacy assessment standards
According to new Chinese medicine treatment angina pectoris guideline of clinical investigations tcm syndrome curative effect determinate standard:
Effective: tcm clinical practice symptom, sign are obviously improved, syndrome integral reduces >=70%.
Effective: tcm clinical practice symptom, sign all take a favorable turn, syndrome integral reduces >=30%.
Invalid: tcm clinical practice symptom, sign are all not improved or increase the weight of, syndrome integral reduces < 30%.
Increase the weight of: tcm clinical practice symptom, sign all have and increase the weight of, syndrome integral reduces < 0.
Computing formula: [before (before treatment the rear integration of integration-treatment) ÷ treatment integration] × 100%.
3 clinical observation result
Table 2 embodiment 3 salvia heart-soothing capsules and commercially available salvia heart-soothing capsules clinical efficacy contrast table
Above-mentioned clinical observation on the therapeutic effect result shows, salvia heart-soothing capsules prepared by the present invention is when treating angina pectoris disease, evident in efficacy higher than commercially available salvia heart-soothing capsules, p < 0.05.
Claims (3)
1. the anginal Chinese medicine for the treatment of, it is characterized in that getting Radix Salviae Miltiorrhizae 1000g, Herba Commelinae 250g, be ground into 60 order coarse powder, employing carbon dioxide supercritical extraction method is extracted, extracting pressure 30 ~ 40Mpa, extraction temperature 30 ~ 40 DEG C, separator pressure 10 ~ 20Mpa, separator temperature 50 ~ 60 DEG C, disengaging time 2 ~ 4 hours, carbon dioxide flow 40 ~ 50L per hour, obtains extracting solution; Get extracting solution 60 DEG C ~ 80 DEG C drying under reduced pressure, get dry extract; Get dry cream and add aspartame 150 ~ 200g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200 ~ 300nm; Get mixing dried cream powder, microcrystalline Cellulose 45 ~ 55g, crospolyvinylpyrrolidone 45 ~ 55g, cross-linking sodium carboxymethyl cellulose 35 ~ 45g, mix homogeneously, with 50 ~ 70% ethanol wet granulations, 60 DEG C ~ 80 DEG C dryings, additional carboxymethyl starch sodium 7 ~ 9g, magnesium stearate 1 ~ 3g, granulate, incapsulates, obtained salvia heart-soothing capsules.
2. the preparation method of Chinese medicine according to claim 1, it is characterized in that getting Radix Salviae Miltiorrhizae 1000g, Herba Commelinae 250g, be ground into 60 order coarse powder, employing carbon dioxide supercritical extraction method is extracted, extracting pressure 30 ~ 40Mpa, extraction temperature 30 ~ 40 DEG C, separator pressure 10 ~ 20Mpa, separator temperature 50 ~ 60 DEG C, disengaging time 2 ~ 4 hours, carbon dioxide flow 40 ~ 50L per hour, obtains extracting solution; Get extracting solution 60 DEG C ~ 80 DEG C drying under reduced pressure, get dry extract; Get dry cream and add aspartame 150 ~ 200g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200 ~ 300nm; Get mixing dried cream powder, microcrystalline Cellulose 45 ~ 55g, crospolyvinylpyrrolidone 45 ~ 55g, cross-linking sodium carboxymethyl cellulose 35 ~ 45g, mix homogeneously, with 50 ~ 70% ethanol wet granulations, 60 DEG C ~ 80 DEG C dryings, additional carboxymethyl starch sodium 7 ~ 9g, magnesium stearate 1 ~ 3g, granulate, incapsulates, obtained salvia heart-soothing capsules.
3. the preparation method of Chinese medicine according to claim 1, get Radix Salviae Miltiorrhizae 1000g, Herba Commelinae 250g, be ground into 60 order coarse powder, employing carbon dioxide supercritical extraction method is extracted, extracting pressure 35Mpa, extraction temperature 35 DEG C, separator pressure 15Mpa, separator temperature 55 DEG C, disengaging time 3 hours, carbon dioxide flow 45L per hour, obtains extracting solution; Get extracting solution 70 DEG C of drying under reduced pressure, get dry extract; Get dry cream and add aspartame 175g, adopt the impact grinding of high energy nanometer to be ground into the mixing dried cream powder of particle diameter 200 ~ 300nm; Get mixing dried cream powder, microcrystalline Cellulose 50g, crospolyvinylpyrrolidone 50g, cross-linking sodium carboxymethyl cellulose 40g, mix homogeneously, with 60% ethanol wet granulation, 70 DEG C of dryings, additional carboxymethyl starch sodium 8g, magnesium stearate 2g, granulate, incapsulates, obtained salvia heart-soothing capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410618752.4A CN104398571A (en) | 2014-11-06 | 2014-11-06 | Red sage root heart-soothing capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410618752.4A CN104398571A (en) | 2014-11-06 | 2014-11-06 | Red sage root heart-soothing capsule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104398571A true CN104398571A (en) | 2015-03-11 |
Family
ID=52636280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410618752.4A Withdrawn CN104398571A (en) | 2014-11-06 | 2014-11-06 | Red sage root heart-soothing capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104398571A (en) |
-
2014
- 2014-11-06 CN CN201410618752.4A patent/CN104398571A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104491018A (en) | Lysimachia christinae hance and radix gentianae tablet and preparation method thereof | |
| CN104491302A (en) | Bone-reunion capsules and preparation method thereof | |
| CN104383251A (en) | Koji capsule and preparation method thereof | |
| CN105456445A (en) | Ulcer-treating capsule and preparation method thereof | |
| CN104225046A (en) | Hyperostosis-resistant tablet and preparation method thereof | |
| CN105727065A (en) | Naoluotong capsule and preparation method thereof | |
| CN105726667A (en) | Refined coronary tablet and preparation method thereof | |
| CN104224945A (en) | Hepatitis B body-resistance-strengthening capsule and preparation method thereof | |
| CN105687339A (en) | Rheumatism relieving capsule and preparation method thereof | |
| CN105769961A (en) | Anti-inflammation (Yanbixiao) capsule and preparation method thereof | |
| CN104224934A (en) | Rhizoma corydalis pain-relieving capsule and preparation method thereof | |
| CN105395501A (en) | Xiaokening tablets and preparing method thereof | |
| CN105708952A (en) | Hepatitis tablet and preparation method thereof | |
| CN105770021A (en) | Pearl and chrysanthemum antihypertension tablet and preparation method thereof | |
| CN105748602A (en) | Rhizoma corydalis pain relieving capsule and preparation method thereof | |
| CN104398850A (en) | Ulcer capsule and preparation method thereof | |
| CN105412301A (en) | Compound salvia miltiorrhiza capsule and preparation method thereof | |
| CN105726811A (en) | Xinbi'an capsule (capsule for treating cardiac diseases) and preparation method of xinbi'an capsule | |
| CN104116785A (en) | Honeysuckle and scutellaria baicalensis capsule and preparation method thereof | |
| CN105726748A (en) | Hyperostosis-treating tablets and preparation method thereof | |
| CN105687891A (en) | Euphorbia humifusa Willd tablet and preparation method thereof | |
| CN104383004A (en) | Parotitis tablets and preparation method thereof | |
| CN104127501A (en) | Quick-acting anti-inflammation capsule and preparation method thereof | |
| CN104383017A (en) | Hulisan tablet and preparation method thereof | |
| CN105343575A (en) | Liyanling tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150311 |